Neural inflammation and the microglial response in diabetic retinopathy

Journal of Ocular Biology, Diseases, and Informatics

Volumn 4, Issue 1-2, 2011, Pages 25-33

  Abcouwer, Steven F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diabetic retinopathy; Leukostasis; Microglia

Indexed keywords

ALMADORI GLYCATED ALBUMIN; C REACTIVE PROTEIN; CD18 ANTIGEN; GLUCOCORTICOID; GLYCOSYLATED ALBUMIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR A; TRANSFORMING GROWTH FACTOR BETA1; TRIAMCINOLONE ACETATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

BLOOD RETINA BARRIER; BRANCH RETINAL VEIN OCCLUSION; CELL ACTIVATION; CENTRAL RETINA VEIN OCCLUSION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOSTASIS; MACROPHAGE; MICROGLIA; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL CHEMOTAXIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RETINA DETACHMENT; RETINITIS; REVIEW; STREPTOZOCIN DIABETES;

EID: 84863990408     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-012-9086-x     Document Type: Review

References (98)

1. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91:461-553.
2. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol. 2011;11:775-87. doi:710.1038/ nri3086.
3. Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia: new concepts. Brain Res Rev. 2007;53:344-54. (Pubitemid 46177241)
4. Graeber MB, Li W, Rodriguez ML. Role of microglia in CNS inflammation. FEBS Lett. 2011;30:30.
5. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559-65. (Pubitemid 40586690)
6. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem. 2007;14:1189-97. (Pubitemid 46739320)
7. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol. 2009;9:429-39.
8. Blach-Olszewska Z, Leszek J. Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders. Neuropsychiatr Dis Treat. 2007;3:365-72. (Pubitemid 47215011)
9. Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience. 2007;147:867-83. Epub 2007 Apr 2024. (Pubitemid 47102534)
10. Polazzi E, Monti B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol. 2010;92:293-315. Epub 2010 Jul 2014.
11. Simard AR, Rivest S. Neuroprotective effects of resident microglia following acute brain injury. J Comp Neurol. 2007;504:716-29. (Pubitemid 350246584)
12. Hume DA, Perry VH, Gordon S. Immunohistochemical localization of a macrophage-specific antigen in developing mouse retina: phagocytosis of dying neurons and differentiation of microglial cells to form a regular array in the plexiform layers. J Cell Biol. 1983;97:253-7. (Pubitemid 13076538)
13. Santos AM, Martin-Oliva D, Ferrer-Martin RM, Tassi M, Calvente R, Sierra A, et al. Microglial response to light-induced photoreceptor degeneration in the mouse retina. J Comp Neurol. 2010;518:477-92.
14. Lee JE, Liang KJ, Fariss RN,Wong WT. Ex vivo dynamic imaging of retinal microglia using time-lapse confocal microscopy. Invest Ophthalmol Vis Sci. 2008;49:4169-76. Epub 2008 May 4116.
15. Xu H, Chen M, Mayer EJ, Forrester JV, Dick AD. Turnover of resident retinal microglia in the normal adult mouse. Glia. 2007;55:1189-98. (Pubitemid 47204210)
16. Kaneko H, Nishiguchi KM, Nakamura M, Kachi S, Terasaki H. Characteristics of bone marrow-derived microglia in the normal and injured retina. Invest Ophthalmol Vis Sci. 2008;49:4162-8. Epub 2008 May 4116.
17. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local selfrenewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538-43. Epub 2007 Nov 1518. (Pubitemid 350175883)
18. Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia. 2011;59:177-87.
19. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544-53. Epub 2007 Nov 1518. (Pubitemid 350175884)
20. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011;14:1142-9. doi:1110.1038/nn.2887.
21. McGeer PL, McGeer EG. History of innate immunity in neurodegenerative disorders. Front Pharmacol. 2011;2:77. Epub 2011 Dec 2012.
22. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314-8. Epub 2005 Apr 1314. (Pubitemid 40746128)
23. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci. 2009;29:3974-80.
24. Griffiths M, Neal JW, Gasque P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int Rev Neurobiol. 2007;82:29-55.
25. Hoarau JJ, Krejbich-Trotot P, Jaffar-Bandjee MC, Das T, Thon-Hon GV, Kumar S, et al. Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol Disord Drug Targets. 2011;10:25-43.
26. Zhang S, Wang XJ, Tian LP, Pan J, Lu GQ, Zhang YJ, et al. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J Neuroinflammation. 2011;8:154.
27. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem. 2011;286:32713-22. Epub 32011 Jul 32719.
28. Hanke ML, Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond). 2011;121:367-87.
29. Tsuda M, Masuda T, Kitano J, Shimoyama H, Tozaki-Saitoh H, Inoue K. IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc Natl Acad Sci USA. 2009;106:8032-7. Epub 2009 Apr 8020.
30. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci. 2007;30:596-602. Epub 2007 Oct 2024. (Pubitemid 350051426)
31. Milner R, Crocker SJ, Hung S,Wang X, Frausto RF, del Zoppo GJ. Fibronectin-and vitronectin-induced microglial activation and matrix metalloproteinase-9 expression is mediated by integrins alpha5beta1 and alphavbeta5. J Immunol. 2007;178:8158-67. (Pubitemid 46898088)
32. Min KJ, Jou I, Joe E. Plasminogen-induced IL-1beta and TNFalpha production in microglia is regulated by reactive oxygen species. Biochem Biophys Res Commun. 2003;312:969-74. (Pubitemid 37490910)
33. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia. 1993;7:111-8.
34. Colton CA, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets. 2010;9:174-91.
35. Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol. 2009;4:399-418. Epub 2009 Aug 2005.
36. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965-75. (Pubitemid 37323217)
37. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4:e8158.
38. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686-94. Epub 2011 Jul 2022.
39. McVicar CM, Hamilton R, Colhoun LM, Gardiner TA, Brines M, Cerami A, et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes. 2011;60:2995-3005. Epub 2011 Sep 2912.
40. Ibrahim AS, El-Shishtawy MM, Zhang W, Caldwell RB, Liou GI. A(A) adenosine receptor (A(A)AR) as a therapeutic target in diabetic retinopathy. Am J Pathol. 2011;178:2136-45.
41. Brucklacher RM, Patel KM, VanGuilder HD, Bixler GV, Barber AJ, Antonetti DA, et al. Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genomics. 2008;1:26.
42. Huang H, Gandhi JK, Zhong X, Wei Y, Gong J, Duh EJ, et al. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2011;52:1336-44. Print 2011 Mar.
43. Wang J, Xu X, Elliott MH, Zhu M, Le YZ. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes. 2010;59:2297-305. Epub 2010 Jun 2298.
44. Lin M, Chen Y, Jin J, Hu Y, Zhou KK, Zhu M, et al. Ischaemiainduced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells. Diabetologia. 2011;54:1554-66. Epub 2011 Mar 1551.
45. Weller M, Esser P, Heimann K, Wiedemann P. Retinal microglia: a new cell in idiopathic proliferative vitreoretinopathy? Exp Eye Res. 1991;53:275-81.
46. Mitamura Y, Takeuchi S, Yamamoto S, Yamamoto T, Tsukahara I, Matsuda A, et al. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy. Jpn J Ophthalmol. 2002;46:218-21. (Pubitemid 34309039)
47. Sakamoto T, Ishibashi T. Hyalocytes: essential cells of the vitreous cavity in vitreoretinal pathophysiology? Retina. 2011;31:222-8.
48. Abu El-Asrar AM, Struyf S, Verbeke H, Van Damme J, Geboes K. Circulating bone-marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes. Acta Ophthalmol. 2011;89:222-8. doi:210.1111/j.1755-3768.2009.01700.x.
49. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126:227-32. (Pubitemid 351240852)
50. Devitt A, Marshall LJ. The innate immune system and the clearance of apoptotic cells. J Leukoc Biol. 2011;90:447-57. Epub 2011 May 2011.
51. McVicar CM, Hamilton R, Colhoun LM, Gardiner TA, Brines M, et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes. 2011;60(11):2995-3005.
52. Tsai GY, Cui JZ, Syed H, Xia Z, Ozerdem U, McNeill JH, et al. Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats. Clin Experiment Ophthalmol. 2009;37:223-31. Epub 2009 Feb 2003.
53. Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res. 2007;32:533-41. (Pubitemid 47039108)
54. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17:463-71.
55. Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41:1971-80. (Pubitemid 30354375)
56. Gaucher D, Chiappore JA, Paques M, Simonutti M, Boitard C, Sahel JA, et al. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47:612-23. Epub 2006 Dec 2019. (Pubitemid 46242159)
57. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46:2210-8.
58. Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep. 2011;11:244-52.
59. Zhang W, Liu H, Rojas M, Caldwell RW, Caldwell RB. Antiinflammatory therapy for diabetic retinopathy. Immunotherapy. 2011;3:609-28.
60. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343-58. Epub 2011 May 2025.
61. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370-8. Epub 2005 Feb 2004. (Pubitemid 40543311)
62. Nguyen TT, Alibrahim E, Islam FM, Klein R, Klein BE, Cotch MF, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32:1704-9. Epub 2009 Jun 1723.
63. Klein BE, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009;127:1175-82.
64. van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300-6. Epub 2005 May 1326. (Pubitemid 41186094)
65. Spijkerman AM, Gall MA, Tarnow L, Twisk JW, Lauritzen E, Lund-Andersen H, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabet Med. 2007;24:969-76. Epub 2007 Jun 2025. (Pubitemid 47301646)
66. Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, et al. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care. 2005;28:714-5. (Pubitemid 40315338)
67. Lim LS, Tai ES, Mitchell P, Wang JJ, Tay WT, Lamoureux E, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4458-63.
68. Ibrahim AS, El-Remessy AB, Matragoon S, Zhang W, Patel Y, Khan S, et al. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes. 2011;60:1122-33. Epub 2011 Feb 1111.
69. Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogenactivated protein kinases in microglia. Glia. 2002;40:175-83. (Pubitemid 35337375)
70. Ibrahim AS, El-Shishtawy MM, Pena Jr A, Liou GI. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis. 2010;16:2033-42.
71. Schalkwijk CG. Comment on "AGEs mediated expression and secretion of TNF alpha in rat retinal microglia" by Dr Wang et al. Exp Eye Res. 2007;85:572-3. author reply 574. Epub 2007 Jul 2015. (Pubitemid 47534205)
72. McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C, et al. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol. 2009;183:2167-75. Epub 2009 Jul 2113.
73. Heasman SJ, Giles KM, Ward C, Rossi AG, Haslett C, Dransfield I. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J Endocrinol. 2003;178:29-36. (Pubitemid 36927006)
74. Walsh GM, Sexton DW, Blaylock MG. Corticosteroids, eosinophils and bronchial epithelial cells: new insights into the resolution of inflammation in asthma. J Endocrinol. 2003;178:37-43. (Pubitemid 36927007)
75. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol. 2010;10:427-39.
76. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One. 2010;5:e13693.
77. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81-100.
78. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-5. (Pubitemid 34293277)
79. Patel N. Targeting leukostasis for the treatment of early diabetic retinopathy. Cardiovasc Hematol Disord Drug Targets. 2009;9:222-9.
80. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007;48:858-65. (Pubitemid 351260723)
81. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501-9. (Pubitemid 34160327)
82. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999;96:10836-41. (Pubitemid 29442230)
83. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000;41:1153-8. (Pubitemid 30187554)
84. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-2. Epub 2004 Jul 1451. (Pubitemid 39561611)
85. He P. Leucocyte/endothelium interactions and microvessel permeability: coupled or uncoupled? Cardiovasc Res. 2010;87:281-90. Epub 2010 May 2013.
86. Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, et al. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2003;17:76-8. Epub 2002 Nov 2015.
87. Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab. 2010;30:459-73. Epub 2009 Nov 2011.
88. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989;84:1045-9. (Pubitemid 19247571)
89. Bell MD, Taub DD, Perry VH. Overriding the brain's intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience. 1996;74:283-92. (Pubitemid 26291164)
90. Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem. 2002;277:10445-51. Epub 12002 Jan 10449. (Pubitemid 34968165)
91. Prinz M, Priller J. Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS. J Neuroimmunol. 2010;224:80-4. Epub 2010 May 2031.
92. Dzenko KA, Song L, Ge S, Kuziel WA, Pachter JS. CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2. Microvasc Res. 2005;70:53-64. Epub 2005 May 2031. (Pubitemid 41565409)
93. Huang D, Wujek J, Kidd G, He TT, Cardona A, Sasse ME, et al. Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice. FASEB J. 2005;19:761-72. (Pubitemid 40617380)
94. Joly S, Francke M, Ulbricht E, Beck S, Seeliger M, Hirrlinger P, et al. Cooperative phagocytes: resident microglia and bone marrow immigrants remove dead photoreceptors in retinal lesions. Am J Pathol. 2009;174:2310-23. Epub 2009 May 2312.
95. Rutar M, Natoli R, Valter K, Provis JM. Early focal expression of the chemokine Ccl2 by Muller cells during exposure to damageinducing bright continuous light. Invest Ophthalmol Vis Sci. 2011;52:2379-88. Print 2011 Apr.
96. Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, Van Rooijen N, et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab. 2005;25:593-606. (Pubitemid 40562932)
97. Woo SJ, Ahn SJ, Ahn J, Park KH, Lee K. Elevated systemic neutrophil count in diabetic retinopathy and diabetes: a hospitalbased cross-sectional study of 30,793 Korean subjects. Invest Ophthalmol Vis Sci. 2011;52:7697-703. Print 2011 Sep.
98. Song H, Wang L, Hui Y. Expression of CD18 on the neutrophils of patients with diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:24-31. Epub 2006 Jul 2018. (Pubitemid 46766726)